Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease

Diabetic Nephropathy Clinical Trial

— MMACKD  

Official title:

The Role of Matrix Metalloproteinases -2 and -9 in Atherosclerosis of Patients With Chronic Kidney Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01458158
• Other study ID #: A13749
• Secondary ID: 31-8-2010
• Status: Recruiting
• Phase: N/A
• First received: September 30, 2011
• Last updated: February 20, 2015
• Start date: October 2011
• Est. completion date: May 2016

Study information

• Verified date: February 2015
• Source: Aristotle University Of Thessaloniki
• Contact: Grigorios G. Dimas
• Phone: +0030 6972321534
• Email: gregorydimas[@]yahoo.gr
• Is FDA regulated: No
• Health authority: Greece: Ethics Committee
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine whether matrix metalloproteinases are associated with atherosclerosis in the different stages of chronic kidney disease.

Description:

The purpose of this study is to determine the correlation of matrix metalloproteinases and atherosclerosis of chronic kidney disease. Patients with diabetes mellitus type 2,as a non-inflammatory leading cause of end stage renal failure and patients with chronic glomerulonephritis and similar course of proteinuria,as an inflammatory leading cause of end stage renal failure are enrolled.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: May 2016
• Est. primary completion date: May 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 50 Years to 75 Years

Eligibility

Inclusion Criteria:

• Chronic kidney disease

• Diabetes mellitus type 2

Exclusion Criteria:

• Malignancy

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Atherosclerosis
• Diabetic Nephropathies
• Diabetic Nephropathy
• Kidney Diseases
• Renal Insufficiency, Chronic

Locations

Country	Name	City	State
Greece	AHEPA University Hospital, Medical School of Aristotle University of Thessaloniki	Thessaloniki

Sponsors (2)

Lead Sponsor	Collaborator
Aristotle University Of Thessaloniki	AHEPA University Hospital

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Association of matrix metalloproteinases with atherosclerosis in patients with chronic kidney disease	Matrix metalloproteinases associated with atherosclerosis in chronic kidney disease;patients with diabetes mellitus type 2 and others with chronic glomerulonephritis.Serum levels of MMPs-2 and -9 are measured by an ELISA system.Intima Media Thickness(IMT) of carotid and femoral arteries is measured with a high resolution ultrasonography.	two years	No
Secondary	Matrix metalloproteinases and atherosclerosis associated with pro-inflammatory and oxidative stress markers in chronic kidney disease	Matrix metalloproteinases associated with atherosclerosis markers,pro-inflammatory markers and markers of oxidative stress in chronic kidney disease	two years	No